BACKGROUND:Autosomal dominant polycystic kidney disease (ADPKD) is a slowly progressive hereditary disorder that usually leads to end-stage renal disease. Although the underlying gene mutations were identified several years ago, efficacious therapy to curtail cyst growth and prevent renal failure is not available. Experimental and observational studies suggest that the mammalian target of rapamycin (mTOR) pathway plays a critical role in cyst growth. METHODS: In this 2-year, double-blind trial, we randomly assigned 433 patients with ADPKD to receive eitherplacebo or the mTOR inhibitor everolimus. The primary outcome was the change in total kidney volume, as measured on magnetic resonance imaging, at 12 and 24 months. RESULTS:Total kidney volume increased between baseline and 1 year by 102 ml in the everolimus group, versus 157 ml in the placebo group (P=0.02) and between baseline and 2 years by 230 ml and 301 ml, respectively (P=0.06). Cyst volume increased by 76 ml in the everolimus group and 98 ml in the placebo group after 1 year (P=0.27) and by 181 ml and 215 ml, respectively, after 2 years (P=0.28). Parenchymal volume increased by 26 ml in the everolimus group and 62 ml in the placebo group after 1 year (P=0.003) and by 56 ml and 93 ml, respectively, after 2 years (P=0.11). The mean decrement in the estimated glomerular filtration rate after 24 months was 8.9 ml per minute per 1.73 m2 of body-surface area in the everolimus group versus 7.7 ml per minute in the placebo group (P=0.15). Drug-specific adverse events were more common in the everolimus group; the rate of infection was similar in the two groups. CONCLUSIONS: Within the 2-year study period,as compared with placebo, everolimus slowed the increase in total kidney volume of patients with ADPKD but did not slow the progression of renal impairment [corrected]. (Funded by Novartis; EudraCT number, 2006-001485-16; ClinicalTrials.gov number, NCT00414440.)
RCT Entities:
BACKGROUND:Autosomal dominant polycystic kidney disease (ADPKD) is a slowly progressive hereditary disorder that usually leads to end-stage renal disease. Although the underlying gene mutations were identified several years ago, efficacious therapy to curtail cyst growth and prevent renal failure is not available. Experimental and observational studies suggest that the mammalian target of rapamycin (mTOR) pathway plays a critical role in cyst growth. METHODS: In this 2-year, double-blind trial, we randomly assigned 433 patients with ADPKD to receive either placebo or the mTOR inhibitor everolimus. The primary outcome was the change in total kidney volume, as measured on magnetic resonance imaging, at 12 and 24 months. RESULTS: Total kidney volume increased between baseline and 1 year by 102 ml in the everolimus group, versus 157 ml in the placebo group (P=0.02) and between baseline and 2 years by 230 ml and 301 ml, respectively (P=0.06). Cyst volume increased by 76 ml in the everolimus group and 98 ml in the placebo group after 1 year (P=0.27) and by 181 ml and 215 ml, respectively, after 2 years (P=0.28). Parenchymal volume increased by 26 ml in the everolimus group and 62 ml in the placebo group after 1 year (P=0.003) and by 56 ml and 93 ml, respectively, after 2 years (P=0.11). The mean decrement in the estimated glomerular filtration rate after 24 months was 8.9 ml per minute per 1.73 m2 of body-surface area in the everolimus group versus 7.7 ml per minute in the placebo group (P=0.15). Drug-specific adverse events were more common in the everolimus group; the rate of infection was similar in the two groups. CONCLUSIONS: Within the 2-year study period,as compared with placebo, everolimus slowed the increase in total kidney volume of patients with ADPKD but did not slow the progression of renal impairment [corrected]. (Funded by Novartis; EudraCT number, 2006-001485-16; ClinicalTrials.gov number, NCT00414440.)
Authors: Wouter N Leonhard; Malu Zandbergen; Kimberley Veraar; Susan van den Berg; Louise van der Weerd; Martijn Breuning; Emile de Heer; Dorien J M Peters Journal: J Am Soc Nephrol Date: 2014-10-31 Impact factor: 10.121
Authors: Vicente E Torres; Kaleab Z Abebe; Arlene B Chapman; Robert W Schrier; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Charity G Moore; Ronald D Perrone Journal: N Engl J Med Date: 2014-11-15 Impact factor: 91.245
Authors: Sharon Anderson; Terry T Oyama; Jessie N Lindsley; William E Schutzer; Douglas R Beard; Vincent H Gattone; Radko Komers Journal: Am J Physiol Renal Physiol Date: 2011-12-07
Authors: Christopher Boehlke; Fruzsina Kotsis; Vishal Patel; Simone Braeg; Henriette Voelker; Saskia Bredt; Theresa Beyer; Heike Janusch; Christoph Hamann; Markus Gödel; Klaus Müller; Martin Herbst; Miriam Hornung; Mara Doerken; Michael Köttgen; Roland Nitschke; Peter Igarashi; Gerd Walz; E Wolfgang Kuehn Journal: Nat Cell Biol Date: 2010-10-24 Impact factor: 28.824
Authors: Cherie Stayner; Justin Shields; Lynn Slobbe; Jonathan M Shillingford; Thomas Weimbs; Michael R Eccles Journal: Nephrology (Carlton) Date: 2012-11 Impact factor: 2.506
Authors: Agnes Hackl; Katrin Mehler; Ingo Gottschalk; Anne Vierzig; Marcus Eydam; Jan Hauke; Bodo B Beck; Max C Liebau; Regina Ensenauer; Lutz T Weber; Sandra Habbig Journal: Pediatr Nephrol Date: 2017-01-12 Impact factor: 3.714